HepG2 cell proliferation

HepG2 cell proliferation refers to the biological process of growth and division in the HepG2 human liver cancer cell line, which was originally derived from the liver tissue of a 15-year-old male with a well-differentiated hepatocellular carcinoma (Aden et al., 1979, Nature). In the context of drug discovery, this is not a specific molecular target (such as a receptor or enzyme) but rather a phenotypic readout or assay endpoint used to evaluate the anti-tumor potential of various compounds (Knowles et al., 1980, Science). The proliferation of these cells is governed by a complex network of signaling pathways, including the Wnt/beta-catenin and MAPK/ERK cascades, which are frequently dysregulated in liver cancer (PubMed: 25635375). Drugs like Sorafenib and Lenvatinib are known to inhibit this proliferation by targeting upstream kinases, thereby inducing cell cycle arrest or apoptosis (Wilhelm et al., 2004, Cancer Res). Because it represents a physiological outcome involving hundreds of interacting proteins, it is classified as a phenotypic response rather than a discrete therapeutic target.

Other names

HepG2 growthHepG2 cell viabilityHepatocellular carcinoma cell proliferationHepG2 cell division

Inhibition of HepG2 proliferation is typically achieved through the antagonism of growth factor receptors (e.g., VEGFR, PDGFR), inhibition of intracellular signaling cascades (e.g., RAF/MEK/ERK, PI3K/AKT/mTOR), or direct interference with DNA replication and cell cycle checkpoints.